The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Steven M. Horwitz; Owen A. O’Connor; Barbara Pro; Lorenz Trümper; Swaminathan P. Iyer; Ranjana H. Advani; Nancy L. Bartlett; Jacob Haaber Christensen; F. Morschhauser; Eva Domingo‐Doménech; Giuseppe Rossi; Woo Seob Kim; Tatyana Feldman; Tobias Menne; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; S.-P. Yeh; Andrei R. Shustov; Andreas Hüttmann; Kerry J. Savage; Sam Yuen; Pier Luigi Zinzani; Harry Miao; Veronica Bunn; Keenan Fenton; Michelle A. Fanale; Markus Puhlmann; Tim Illidge

doi:10.1016/j.annonc.2021.12.002

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Horwitz et al. (2021) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d50 https://doi.org/10.1016/j.annonc.2021.12.002

View Full Paper

Ask AI

Bookmark

Share

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading